Who are Rhenium-188-HEDP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Technetium Tc99m Sestamibi, Copper Cu 64 Dotatate, Sr-89, Tc 99m filtered sulfur colloid, Tc-99m Pentetate, Rubidium-82.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhenium-188-hedp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rhenium-188-HEDP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rhenium-188-HEDP (Rhenium-188-HEDP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical. Area: Oncology.

phase 3 Radiopharmaceutical Bone hydroxyapatite (via HEDP bisphosphonate moiety) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Rhenium-188-HEDP (Rhenium-188-HEDP) — Amsterdam UMC, location VUmc. Rhenium-188-HEDP is a radiopharmaceutical that localizes to areas of increased bone metabolism and delivers beta radiation directly to bone lesions for pain palliation and potential therapeutic benefit.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Rhenium-188-HEDP TARGET	Rhenium-188-HEDP	Amsterdam UMC, location VUmc	phase 3	Radiopharmaceutical	Bone hydroxyapatite (via HEDP bisphosphonate moiety)
Technetium Tc99m Sestamibi	Technetium Tc99m Sestamibi	Lantheus Medical Imaging	marketed	Radiopharmaceutical imaging agent	Mitochondrial membrane potential
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)
Sr-89	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism
Tc 99m filtered sulfur colloid	Tc 99m filtered sulfur colloid	Memorial Health University Medical Center	marketed	Radiopharmaceutical diagnostic agent
Tc-99m Pentetate	Tc-99m Pentetate	NYU Langone Health	marketed	Radiopharmaceutical diagnostic agent
Rubidium-82	Rubidium-82	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	marketed	PET radiopharmaceutical	Na+/K+-ATPase pump (myocardial uptake mechanism)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical class)

Amsterdam UMC, location VUmc · 1 drug in this class
Blue Earth Diagnostics · 1 drug in this class
Brigham and Women's Hospital · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
IRCCS San Raffaele · 1 drug in this class
ITEL Telecomunicazioni Srl · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Michael C Roarke, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rhenium-188-HEDP — Competitive Intelligence Brief. https://druglandscape.com/ci/rhenium-188-hedp. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing